Now onto a Aimovig on Slide 14. To begin the unmet need for migraine is substantial. There are approximately 4 million individuals in the U.S. alone who take preventative medications for migraines. However, compliance, as well as 75% discontinued therapy after only a year. Approximately 200,000 new patients in the US have now tried Aimovig since it launched less than a year ago and there remains a significant opportunity for growth as CGRP penetration of the overall market is low.